



| Indikation: | Studententitel: | Leiter klinische Prüfung: | Ansprechpartner: |
|------------------------------------|--|---|--|
| allogene Stammzell-transplantation | Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02). | Prof. Dr. med. Nicolaus Kröger | Prof. Dr. med. Wolfgang Bethge, Tübingen |
| allogene Stammzell-transplantation | Registry of the therapeutic impact and quality of life of patients with graft versus host disease undergoing extracorporeal photopheresis. | Prof. Dr. med. Wolfgang Bethge, Tübingen | Prof. Dr. med. Wolfgang Bethge, Tübingen |
| allogene Stammzell-transplantation | Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML. (ETAL3-ASAP). | Prof. Dr. med. Johannes Schetelig, Dresden | Prof. Dr. med. Wolfgang Bethge, Tübingen |
| allogene Stammzell-transplantation | Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications (PACT2014-001). | PD Dr. med. Götz Ulrich Grigoleit, Würzburg | Prof. Dr. med. Wolfgang Bethge, Tübingen |
| allogene Stammzell-transplantation | A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients (SHP620-302) | Prof. Dr. med. Wolfgang Bethge, Tübingen | Prof. Dr. med. Wolfgang Bethge, Tübingen |
| allogene Stammzell-transplantation | A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor (HAMLET). | Prof. Dr. med. Johannes Schetelig Dresden | Prof. Dr. med. Wolfgang Bethge, Tübingen |



allogene
Stammzell-
transplantation

A Phase 3 Study of Itacitinib or Placebo
in Combination with Corticosteroids as
Initial Treatment for Chronic Graft-
versus-Host Disease.
(GRAVITAS-309)

Prof. Dr. med.
Matthias
Stelljes,
Münster

Prof. Dr. med.
Wolfgang Bethge,
Tübingen